The “IP 102” pill is a prescription capsule containing 300 mg of Gabapentin. Manufactured by Amneal Pharmaceuticals, it is classified as an anticonvulsant and neuropathic pain agent, most commonly prescribed to manage nerve pain (such as postherpetic neuralgia from shingles) and as an adjunctive therapy for focal (partial) seizure
Pill Identification
Attribute – Visual & Chemical Characteristics
- Imprint – Stamped IP 102 on both the cap and body
- Active Ingredient – Gabapentin (300 mg)
- Color & Shape – Beige / buff-colored, oblong hard gelatin capsule (approx. 19 mm)
- Drug Class – Anticonvulsant / GABA Analog
- Prescription Status – Prescription Only (Rx); controlled substance in select U.S. states
- Manufacturer – Amneal Pharmaceuticals
- (Note: While gabapentin 300 mg is produced by various manufacturers using different colors or imprints, the “IP 102” code specifically denotes Amneal’s 300 mg generic formulation).
Mechanism of Action
Despite being a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA), gabapentin does not bind directly to GABA-A or GABA-B receptors, nor does it convert into GABA or alter GABA uptake.
- Alpha-2-Delta Binding: Gabapentin selectively binds with high affinity to the auxiliary subunit of voltage-gated calcium channels in central nervous system (CNS) tissues.
- Reduction of Neurotransmitter Release: By modulating these presynaptic calcium channels, gabapentin decreases the influx of calcium ions into nerve terminals.
- Suppression of Hyperexcitability: This inhibition reduces the presynaptic release of excitatory neurotransmitters – including glutamate, substance P, and norepinephrine – calming overactive neuronal pain signaling and preventing seizure propagation.
Dosing & Administration
Gabapentin dosing must be individually titrated by a healthcare professional based on the condition being treated and renal function.
- Postherpetic Neuralgia (Shingles Nerve Pain):
- Starting Schedule: Day 1: 300 mg once daily; Day 2: 300 mg twice daily; Day 3: 300 mg three times daily.
- Maintenance Dose: 900 mg to 1,800 mg total daily dose, divided into 3 equal doses.
- Partial-Onset Seizures (Adults & Children 12+):
- Effective Range: 900 mg to 1,800 mg daily, divided three times per day.
- Maximum Dose: Doses up to 2,400 mg or 3,600 mg daily may be used under close neurological monitoring.
- Key Administration Rules:
- Swallow capsules whole with water; do not crush, open, or chew them.
- Space doses evenly throughout the day. The maximum gap between evening and morning doses should not exceed 12 hours to maintain seizure coverage.
- Can be taken with or without food.
Common Side Effects
Because gabapentin depresses central nervous system activity, side effects primarily involve sedation and motor control.
Frequency – Side Effects
- Very Common (>10%) = Drowsiness / Somnolence, Dizziness, Unsteadiness / Ataxia, Fatigue
- Common (1–10%) – Peripheral edema (swelling of lower legs/feet), rapid eye movement (nystagmus), tremors, double vision (diplopia), dry mouth, weight gain
- Pediatric Specific (Ages 3–12) | Emotional lability, behavioral problems, hyperkinesia (restlessness), hostility |
Drug Interactions & Precautions
- Opioids & CNS Depressants: Co-administration with opioids (e.g., oxycodone, morphine, tramadol), benzodiazepines, or alcohol severely intensifies central nervous system depression, risking profound sedation and life-threatening respiratory depression.
- Aluminum/Magnesium Antacids: Antacids containing magnesium hydroxide or aluminum hydroxide (e.g., Mylanta, Maalox) decrease gabapentin absorption by approximately 20%. Separate administration by at least 2 hours.
- Renal Impairment: Gabapentin is eliminated entirely by renal excretion without liver metabolism. Patients with reduced kidney function or those on hemodialysis require dosage reduction.
- Elderly Patients: Increased risk of confusion, loss of balance, and fall-related injuries; lower initial doses are recommended.
Black Box & FDA Safety Warnings
- Respiratory Depression Warning: The FDA warns that serious, life-threatening breathing difficulties may occur in patients using gabapentin who have pre-existing respiratory risk factors-such as Chronic Obstructive Pulmonary Disease (COPD) or asthma-older adults, or when combined with CNS depressants like opioids.
- Suicidal Thoughts & Behaviors: Antiepileptic drugs, including gabapentin, increase the risk of suicidal thoughts or behaviors in about 1 in 500 patients. Patients should be monitored for sudden shifts in mood, worsening depression, or unusual behavioral changes.
- Avoid Abrupt Discontinuation: Never stop taking gabapentin suddenly. Abrupt cessation can trigger withdrawal symptoms (anxiety, insomnia, nausea, sweating) or precipitate status epilepticus (rebound seizures) in epilepsy patients. Tapering must occur gradually over at least 1 week under medical guidance.